PDP1 and glioblastoma: Interestingly, promoting pyruvate dehydrogenase (PDH) activity with dichloroacetate (DCA) presents promising results with minor side effects in early phase clinical trials with glioblastoma patients by suppressing angiogenesis, increasing mitochondrial ROS, inducing apoptosis, blocking HIF1 signaling and activating tumor suppressor p53 [250–252].